Board of Directors Gerald Solensky Jr. | Executive Chairman As Chairman and CEO of Zomedica, Gerald Solensky is determined to revolutionize the animal health industry by building an unprecedented business model alongside a world-class leadership team. With a 20-year track record building successful operations within start-up, turnaround and rapid-change environments, Gerald is committed to helping animals by ensuring the success of the veterinarians who care for them. Gerald began his career with Yamaha Motors as the youngest executive to command national and international accounts averaging US$50 million in total sales. He entered the banking industry serving as Regional Vice President of Fifth Third Bank, where he managed US$250 million portfolio, and subsequently as Senior Vice President at IndyMac Bank where he managed the P&L statement in the mortgage-backed security division. Before joining Zomedica, Gerald served as Director, President and CEO at Dynamic Fuel Systems (now dynaCERT Inc.), a TSX-V listed fuel system technology firm. Most recently, Gerald completed over 800 observation hours in pre-veterinary medicine to garner a more complete understanding of Zomedica’s veterinary customer and their associated needs. Jane Eagleson, BVSc | Independent Member A veterinarian with more than 30 years of experience in animal health pharmaceutical development, Jane Eagleson is currently Vice President of Clinical and Regulatory Affairs at Nexvet Biopharma, a veterinary biotherapeutics company. She concurrently serves as owner of Bleecker Street Consulting, an animal health consulting firm that specializes in pharmaceutical development strategy in North America, Europe and the Oceania markets. Jane held various senior leadership positions with Argenta, a pharmaceutical contract research and contract manufacturing organization. Prior to that, she served in several senior director roles with Pfizer, Inc., leaving the company as Senior Director of Asian Business Development where she was responsible for strategic planning and execution of Asian business initiatives for both animal health and human health organizations. Before Pfizer, Jane was a Director with Merial and a Research Veterinarian with Merck Animal Health. She has a Master of Veterinary Science in immunology from Massey University and Bachelor of Veterinary Science (U.S. DVM equivalent) from the University of Sydney. She has also authored more than 35 publications in peer reviewed journals. James LeBar | Independent Member With more than 40 years of experience as an entrepreneur and executive leader, James “Jim” LeBar is an expert in building and operating start-up companies and establishing corporate structures for profitability and success. He served as president and CEO of numerous Canadian companies and was founder and operator of the largest importer of seafood products in North America. His supreme talent for sales and customer service have directly contributed to profitable market expansions for enterprises throughout North America. Most recently serving as a turnaround consultant for a specialized health training company, Jim transformed operations and established realistic sales goals, taking the company from negative to positive cash flow in under 12 months. His consulting experience further complements his accomplished background in investor and customer communications and regulatory compliance specific to imports and exports. William C. MacArthur, MS, DVM | Executive Member As Zomedica’s Chief Medical Officer and Director of R&D, Dr. MacArthur converges his first-hand experience in clinical veterinary practice with his animal biotechnology expertise to develop high-value products that address the unmet needs of companion animal veterinarians. Prior to joining Zomedica, Dr. MacArthur was the founder, CEO and Institutional Veterinarian of the small cap biotechnology startup GeneWorks, which established a post-money valuation of US$35 million. He subsequently owned and operated a six-doctor small animal clinical practice, where he excelled at solving difficult diagnoses. Dr. MacArthur earned Bachelor of Science degrees in zoology, biochemistry, and chemistry from the University of Massachusetts Amherst, a Master of Science in cellular and molecular biology from the University of Michigan, and doctor of veterinary medicine from Michigan State University. Shameze Rampertab, CPA, CA | Executive Member Based in Canada, Shameze Rampertab is Zomedica’s Chief Financial Officer and corporate secretary. He leads the company’s finance operations to maximize profitability, shareholder value and brand excellence. With 20 years of experience in the life science sector, Shameze has served as chief financial officer for multiple publicly traded healthcare startups, worked as an investment banker, and thrived as a sell-side health-equity research analyst. Before joining Zomedica, Shameze served as CFO and secretary at Profound Medical Corp., a TSX-V listed medical device company, and as CFO and Vice President of Finance for Intellipharmaceutics International Inc., a NADSAQ and TSX listed pharmaceutical company. He received his chartered professional accountant (CPA) and chartered accountant (CA) designations from the Canadian Institute of Chartered Accountants after earning his MBA from McMaster University and Bachelor of Science in molecular genetics and molecular biology from the University of Toronto. Tom Robitaille | Independent Member An international business leader with 30 years of animal health experience, Tom Robitaille is currently Vice President of Veterinary Channel Development at Blue Buffalo Company, a premium, all-natural pet food company. Before joining Blue Buffalo, Tom held various director level and senior management positions during his 19-year career with the animal health pharmaceutical company Vetoquinol SA Inc. As the Americas Group Director he managed affiliates and regional distributors in Canada, USA, Mexico and Brazil. He was responsible for veterinary pharmaceutical operations in the United Kingdom, Ireland, Belgium, and the Netherlands as Managing Director and also served as Director of International Development, where he contributed to an increase in sales and profit for in Eastern Europe, Asia Pacific, Africa, and Latin America. Before Vetoquinol, Tom was a Product Manager with Elanco, the animal health division of Eli Lilly and Company, and started his animal health career serving in various sales and marketing positions throughout Canada, USA, Europe and the Middle East with Sandoz, a generic pharmaceuticals company. He has a Master of Business Administration from the University of Warwick and Bachelor of Science degree from Concordia University. Jeff Rowe | Independent Member With over 30 years of experience in the specialty pharmacy industry, Jeff Rowe most recently served as Executive Vice President and board member of Diplomat Inc., the largest independent specialty pharmacy company in the United States. During his tenure with Diplomat, the company grew from a single location with less than US$5 million in revenue, to 16 locations and US$3 billion in sales, and became publicly traded on the New York Stock Exchange. Prior to that, Jeff owned two successful community pharmacies in Genesee County, Michigan. An authority in pharmaceutical operations, Jeff offers critical insights into fundamental business strategies involving accreditation, contracting, cybersecurity and regulation, combined with an expertise in compounding and integrative medicine. He is uniquely qualified to identify process improvements and efficiencies while maintaining compliance and quality standards, for increased revenue, profitability and customer satisfaction. Jeff holds a Bachelor of Pharmacy degree from Ferris State University and has completed many health-related credential courses. Rodney J. Williams | Independent Member With over 20 years of medical technology and related healthcare experience, Rodney “Rod” Williams successfully guided both large and small cap companies through growth cycles, while strengthening product portfolios and boosting commercial planning competencies. He is an entrepreneur-in- residence with PTV Healthcare Capital, a private equity investment firm known for transforming early and middle-market companies into efficient and diversified businesses with superior growth profiles. Rod is the former President and CEO of Heart Rhythm Society Consulting Services where he established specific business services to improve the operating performance and profitability of hospitals, integrated delivery networks, and cardiology practices. He also served in senior executive positions with St. Jude Medical, GE Healthcare, Johnson and Johnson, and Bausch & Lomb. Rod earned his MBA and Bachelor of Science degree from the University of Southern California and attended the General Management Executive Leadership Program at The Wharton School of Business.